The DOI matches its Crossref record.
The evolution of drug–resistant malaria: the role of drug elimination half–life
Open accessAbstract
This paper seeks to define and quantify the influence of drug elimination half–life on the evolution of antimalarial drug resistance. There are assumed to be three general classes of susceptibility of the malaria parasite Plasmodium falciparum to a drug: Res0 , the original, susceptible wildtype; Res1 , a group of intermediate levels of susceptibility that are more tolerant of the drug but still cleared by treatment; and Res2 , which is completely resistant to the drug. Res1 and Res2 resistance both evolve much faster if the antimalarial drug has a long half–life. We show that previous models have significantly underestimated the rate of evolution of Res2 resistance by omitting the effects of drug half–life. The methodology has been extended to investigate (i) the effects of using drugs in combination, particularly when the components have differing half–lives, and (ii) the specific example of the development of resistance to the antimalarial pyrimethamine–sulphadoxine. An important detail of the model is the development of drug resistance in two separate phases. In phase A, Res1 is spreading and replacing the original sensitive forms while Res2 remains at a low level. Phase B starts once parasites are selected that can escape drug action ( Res1 genotypes with borderline chemosensitivity, and Res2 ): these parasites are rapidly selected, a process that leads to widespread clinical failure. Drug treatment is clinically successful during phase A, and health workers may be unaware of the substantial changes in parasite population genetic structure that predicate the onset of phase B. Surveillance programs are essential, following the introduction of a new drug, to monitor effectively changes in treatment efficacy and thus provide advance warning of drug failure. The model is also applicable to the evolution of antibiotic resistance in bacteria: in particular, the need for these models to incorporate drug pharmacokinetics to avoid potentially large errors in their predictions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
White, N. J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421682 · Cited by 1,248
Self-citationMechanisms of Resistance of Malaria Parasites to Antifolates
Gregson, A., & Plowe, C. V. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.4 · Cited by 499
Malaria ecology along the Thailand-Myanmar border.
Parker, D. M., Carrara, V. I., Pukrittayakamee, S., McGready, R., & Nosten, F. H. (2015) · Malaria Journal · doi:10.1186/s12936-015-0921-y · Cited by 142
DETECTION OF PLASMODIUM FALCIPARUM IN PREGNANCY BY LASER DESORPTION MASS SPECTROMETRY
NYUNT, M., PISCIOTTA, J., FELDMAN, A. B., THUMA, P., SCHOLL, P. F., DEMIREV, P. A., LIN, J. S., SHI, L., KUMAR, N., & SULLIVAN, D. J. (2005) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2005.73.485 · Cited by 43
Metadata
- Authors
- Hastings, I. M., Watkins, W. M., & White, N. J.
- Venue
- Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences
- Publisher
- The Royal Society
- Published
- 2002-04-29
- Volume
- 357
- Issue
- 1420
- Pages
- 505-519
- ISSN
- 0962-8436 (ISSN-L)
- 1471-2970
- OpenAlex
- W1990484067
- Cited by
- 202
- References
- 0
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The evolution of drug–resistant malaria: the role of drug elimination half–life. https://app.cochat.ai/papers/10.1098/rstb.2001.1036
- The paper
- Hastings, I. M., Watkins, W. M., & White, N. J. (2002). The evolution of drug–resistant malaria: the role of drug elimination half–life. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences. https://doi.org/10.1098/rstb.2001.1036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.